Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 155

1.

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.

Mross K, Richly H, Frost A, Scharr D, Nokay B, Graeser R, Lee C, Hilbert J, Goeldner RG, Fietz O, Scheulen ME.

Cancer Chemother Pharmacol. 2016 Aug;78(2):405-17. doi: 10.1007/s00280-016-3095-6. Epub 2016 Jun 27.

2.

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B.

J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4.

PMID:
26952006
3.

Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).

Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Prausová J, Van Laethem JL, Cascinu S, Ajani JA.

J Gastrointest Cancer. 2015 Jun;46(2):109-17. doi: 10.1007/s12029-014-9680-1.

PMID:
25707610
4.

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.

Weihrauch MR, Richly H, von Bergwelt-Baildon MS, Becker HJ, Schmidt M, Hacker UT, Shimabukuro-Vornhagen A, Holtick U, Nokay B, Schroff M, Wittig B, Scheulen ME.

Eur J Cancer. 2015 Jan;51(2):146-56. doi: 10.1016/j.ejca.2014.11.002. Epub 2014 Dec 2.

PMID:
25480557
5.

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H.

Eur J Cancer. 2015 Jan;51(1):27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5.

PMID:
25459392
6.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K, Le N.

Eur J Cancer. 2014 Aug;50(12):2072-81. doi: 10.1016/j.ejca.2014.04.024. Epub 2014 Jun 7.

PMID:
24915778
7.

FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.

Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):642-52. doi: 10.5414/CP202109.

PMID:
24800922
8.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.

Ann Oncol. 2014 Mar;25(3):742-6. doi: 10.1093/annonc/mdt585. Epub 2014 Feb 7.

9.

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.

Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D.

Br J Cancer. 2014 Mar 4;110(5):1155-62. doi: 10.1038/bjc.2013.826. Epub 2014 Jan 16.

10.

First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, Scheulen ME.

PLoS One. 2013 Dec 13;8(12):e83232. doi: 10.1371/journal.pone.0083232. eCollection 2013.

11.

Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.

Slingerland M, Guchelaar HJ, Rosing H, Scheulen ME, van Warmerdam LJ, Beijnen JH, Gelderblom H.

Clin Ther. 2013 Dec;35(12):1946-54. doi: 10.1016/j.clinthera.2013.10.009. Epub 2013 Nov 28.

PMID:
24290734
12.

Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.

Welt A, Tewes M, Aktas B, O Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S.

Breast Cancer Res Treat. 2013 Nov;142(1):81-8.

PMID:
24122392
13.

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN.

Breast Cancer Res Treat. 2013 Jul;140(2):331-9. doi: 10.1007/s10549-013-2632-9. Epub 2013 Jul 19.

PMID:
23868188
14.

Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.

Metz CH, Scheulen M, Bornfeld N, Lohmann D, Zeschnigk M.

Cancer Med. 2013 Apr;2(2):208-15. doi: 10.1002/cam4.61. Epub 2013 Feb 14.

15.

A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.

Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E.

J Cardiovasc Pharmacol. 2013 Jun;61(6):495-504. doi: 10.1097/FJC.0b013e31828b73ff.

PMID:
23429593
16.

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.

Plummer R, Madi A, Jeffels M, Richly H, Nokay B, Rubin S, Ball HA, Weller S, Botbyl J, Gibson DM, Scheulen ME.

Cancer Chemother Pharmacol. 2013 Jan;71(1):93-101. doi: 10.1007/s00280-012-1982-z. Epub 2012 Oct 11.

17.

Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.

Westekemper H, Freistuehler M, Bornfeld N, Steuhl KP, Scheulen M, Hilger RA.

Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):279-84. doi: 10.1007/s00417-012-2083-8. Epub 2012 Jul 11.

PMID:
22782301
18.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE.

Clin Cancer Res. 2012 Sep 1;18(17):4794-805. Epub 2012 Jul 5.

19.

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME.

Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14.

20.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K.

Br J Cancer. 2012 May 22;106(11):1722-7. doi: 10.1038/bjc.2012.153. Epub 2012 May 8.

Supplemental Content

Loading ...
Support Center